Streetbeat News

GHRS

GH Research PLC

https://www.ghres.com

Industry

Biotechnology

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on GH Research (NASDAQ:GHRS) and raises the price target from $30 to $31.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 5:32 pm

GH Research (NASDAQ:GHRS) reported Q1 EPS of $(0.15), surpassing the $(0.22) estimate, marking a 31.82% beat and a 28.57% improvement from last year's $(0.21) per share loss. The company's cash and marketable securities stood at $214.0M as of March 31.

Portfolio Pulse from Benzinga Newsdesk

May 03, 2024 | 11:08 am

Beckley Psytech and atai Life Sciences announced positive results from a Phase 2a study of 5-MeO-DMT for Treatment Resistant Depression. Utah hospitals will soon offer psilocybin and MDMA therapy. Elon Musk discussed the benefits of ketamine for depression and its positive impact on investors. Meta is under investigation for potentially facilitating illegal drug sales. MindMed's CEO highlighted LSD's potential in a podcast. Various companies and ETFs are mentioned with their stock performance.

Portfolio Pulse from Lara Goldstein

March 29, 2024 | 4:43 pm

Cybin Inc. received FDA Breakthrough Therapy designation for its psilocybin therapy for Major Depressive Disorder, alongside positive clinical data and a $150M private placement. MindMed also received the designation for its LSD-derived treatment for Generalized Anxiety Disorder, with expected proceeds of $175M from share offerings. Gilgamesh Pharmaceuticals was awarded a $14M grant for ibogaine analog research. Psyence Biomedical, Red Light Holland, and Clearmind Medicine were mentioned for their developments in psychedelics. The article also covered stock performances of several psychedelics companies.

Portfolio Pulse from Lara Goldstein

March 20, 2024 | 6:49 pm

Clinical trials show psilocybin-assisted therapy's potential for treating Generalized Anxiety Disorder. Incannex Healthcare (NASDAQ:IXHL) conducted the Phase 2 study. Enveric Biosciences (NASDAQ:ENVB) announced non-binding deals to license drug compounds for mental health treatments. Compass Pathways (NASDAQ:CMPS), GH Research (NASDAQ:GHRS), MindMed (NASDAQ:MNMD), and other companies reported financial results and business updates. AdvisorShares Psychedelics ETF (NYSE:PSIL) and several US-listed companies showed varied stock performance.

Portfolio Pulse from Lara Goldstein

March 04, 2024 | 6:48 pm

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on GH Research (NASDAQ:GHRS), maintaining a $40 price target.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 6:08 pm

JMP Securities analyst Jason Butler maintains a Market Outperform rating on GH Research (NASDAQ:GHRS) but lowers the price target from $50 to $39.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 4:52 pm

GH Research (NASDAQ:GHRS) reported Q4 earnings with an EPS of $-0.21, missing estimates by -5.0% and showing no revenue change from the previous year. Despite beating EPS estimates last quarter, this miss could impact investor sentiment.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:00 pm

GH Research reported a fiscal year 2023 net loss of $35.6 million, or a loss of $0.68 per share, compared to a net loss of $22.5 million, or $0.43 per share, in the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 12:19 pm

A new study highlights the potential of psychedelics like LSD and magic mushrooms in improving sexual function. The FDA has accepted an NDA from Lykos Therapeutics for MDMA-assisted therapy for PTSD, marking a significant step towards integrating psychedelic therapies into mainstream medicine. Despite the growing interest and decriminalization efforts in several states, federal law still prohibits psilocybin. Canadian research supports psilocybin therapy for end-of-life distress, and a Washington doctor is challenging the DEA for approval to use it with terminally ill patients. The psychedelics sector, including companies like Numinus Wellness and various psychedelics stocks, shows signs of growth and investor interest.

Portfolio Pulse from Lara Goldstein

February 15, 2024 | 1:36 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.